Therapeutic Zinc in Childhood Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00252304|
Recruitment Status : Completed
First Posted : November 11, 2005
Last Update Posted : October 6, 2009
|Condition or disease||Intervention/treatment||Phase|
|Pneumonia||Drug: Zinc (zinc sulphate) Drug: Placebo||Phase 2 Phase 3|
Nepal has an under-five mortality rate of 91/1000 live births. Pneumonia, one of the major killers accounts for the death of 25,000 - 35,000 Nepalese children every year. It is estimated that, on an average, of 1000 children <5 years of age that visit health facilities, 90 have pneumonia of which 4.2 have severe pneumonia. At the Kanti Children's Hospital, respiratory diseases are the most frequent reason for admission and the second most frequent cause of child death Zinc, an important micronutrient, is crucial for the normal function of the immune system as well as the integrity of the respiratory epithelium. Zinc deficiency is associated with an increased incidence and severity of diarrhea and respiratory tract infections. The preventive effect of zinc on diarrheal and respiratory illness has been well documented.
Early in an infection zinc is shifted into the liver from the plasma, bone, skin and intestines. For a child with initial low zinc levels, even relatively trivial infections may cause entry into the vicious cycle of reduced plasma zinc and increased infection severity. Administration of zinc during the acute illness may help in reducing the severity of illness.
The therapeutic effect of zinc in acute diarrhea has been well documented. In a study conducted at Bhaktapur, Nepal, in children 6 to 36 months of age, supplementation with zinc was found to be highly effective in the treatment of acute diarrhea.
The Kanti Children's Hospital in Kathmandu serves as a general and referral hospital for children from all parts of the country. Approximately 25% of all admissions to this hospital are due to pneumonia. Being the only well recognized children's hospital, there is always a constraint for available beds for children presenting with pneumonia. Zinc as an adjuvant to standard treatment of pneumonia with antimicrobials was found to hasten recovery from severe pneumonia in children less than 2 years of age in Bangladesh . If we were to conduct a similar study and prove that zinc does in fact help to shorten the duration of illness in children with severe pneumonia, it would go a long way in contributing to improve case management.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||641 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Efficacy of Zinc as Adjuvant Therapy in the Treatment of Severe Pneumonia in Nepalese Children at the Kanti Children's Hospital|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||July 2008|
Zinc sulphate 10 or 20 mg per day
Drug: Zinc (zinc sulphate)
Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Placebo Comparator: Placebo
- Time to cessation of severe pneumonia [ Time Frame: Within 2 weeks after enrollment ]
- The period starting from enrolment to the beginning of a 24-hour consecutive period of absence of lower chest indrawing, of hypoxia and of any danger signs. [ Time Frame: Recovery from pneumonia within 2 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00252304
|Kanti Children Hospital|
|Principal Investigator:||Sudha Basnet, MD||Department of Child Health, Institute of Medicine, Tribhuwan University, Katmandu, Nepal|
|Study Director:||Tor A Strand, MD, PhD||Centre For International Health|
|Study Chair:||Halvor Sommerfelt, MD, PhD||Centre For International Health|
|Study Chair:||Nita Bhandari, MBBS, PhD||Centre For International Health|
|Study Director:||Prakash S Shrestha, MD||Child Health Research Project, Department of Child Health, Institute of Medicine, Maharajganj:|
|Study Chair:||Ramesh K Adhikari, MD||Child Health Research Project, Department of Child Health, Institute of Medicine, Maharajganj:|